Power-law temporal autocorrelation of activity reflects severity of parkinsonism
Power-law temporal autocorrelation of activity reflects severity of parkinsonism
复制标题
DOI：
10.1002/mds.21527
复制
发表时间：
2007-07-15
影响因子：
8.6
通讯作者：
Kwak, Shin
中科院分区：
文献类型：
--
作者：
Pan, Weidong;Ohashi, Kyoko;Kwak, Shin
我们的目的是获得一个可靠的，客观的规模代表疾病的严重程度，适当的管理帕金森病（PD）患者。根据Hoehn-Yahr评分将东京大学医院神经内科的19名PD患者分为轻度组（n = 10）或重度组（n = 9），并在手腕上佩戴加速度计连续6天以上。在此期间，我们监测了他们对症状严重程度的主观评估，并分析了活动时间序列中局部最大值和最小值波动的幂律指数（a）。统计学比较严重和轻度组和个别患者的“良好状态”和“不良状态”的日子，以及抗帕金森病药物治疗前后的日子。在所有的患者中，当帕金森症是轻度的时候，局部最大值的a总是低于严重的时候。震颤的存在不影响局部最大值的a。由于活动记录中局部最大波动的α值较低，反映了从低到高的体力活动或运动不能的严重程度更频繁的转换行为，因此活动记录仪监测帕金森病及其幂律相关性的分析可能为门诊控制帕金森病和评估新的抗帕金森病药物提供有用的客观信息。(c)2007运动障碍协会
We aimed to obtain a reliable, objective scale representing disease severity for appropriate management of patients with Parkinson's disease (PD). Nineteen patients with PD at the Department of Neurology, Tokyo University Hospital, were classified into mild (n = 10) or severe groups (n = 9) depending on their Hoehn-Yahr scores, and wore accelerometers on their wrists for more than 6 consecutive days. During this time we monitored their subjective assessments of symptom severity and analyzed the power-law exponents (a) for local maxima and minima of fluctuations in the activity time series. Statistical comparisons were made between the severe and mild groups and of individual patients on "good condition" and "bad condition" days, as well as between days before and after antiparkinsonism medication. In all patients, the a for local maxima was always lower when parkinsonism was mild than when severe. Presence of tremor did not influence the a for local maxima. As the lower alpha value for local maxima of fluctuations in activity records reflects more frequent switching behavior from low to high physical activities or the severity of akinesia, actigraph monitoring of parkinsonism, and analysis of its power-law correlation may provide useful objective information for controlling parkinsonism in outpatient clinics and for evaluating new antiparkinsonism drugs. (c) 2007 Movement Disorder Society